- Shares of Enanta (ENTA -15.4%) are getting hit hard in morning trading.
- Likely behind the move is upbeat data from GILD regarding impressive SVR12 rates from Phase 3 studies of a sofosbuvir/ledipasvir combo in GT1 HCV.
- ENTA discovered ABT-450, one of the compounds in ABBV's 3D GT1 HCV regimen.
- For more on ENTA/ABBV, see here and here.
Enanta falls after Gilead HCV data
Dec 18 2013, 10:56 ET